APA (7th ed.) Citation

Chan, A., Alroughani, R., Calabrese, M., Havrdová, E. K., Obeidat, A. Z., Schmierer, K., . . . de Seze, J. (2026). International Expert Opinion on Optimal Switching to Cladribine Tablets from Other High-Efficacy Disease-Modifying Therapies for Relapsing–Remitting Multiple Sclerosis: Opportunities and Challenges. Neurology & Therapy, 15(3), 887. https://doi.org/10.1007/s40120-026-00901-7

Chicago Style (17th ed.) Citation

Chan, Andrew, et al. "International Expert Opinion on Optimal Switching to Cladribine Tablets from Other High-Efficacy Disease-Modifying Therapies for Relapsing–Remitting Multiple Sclerosis: Opportunities and Challenges." Neurology & Therapy 15, no. 3 (2026): 887. https://doi.org/10.1007/s40120-026-00901-7.

MLA (9th ed.) Citation

Chan, Andrew, et al. "International Expert Opinion on Optimal Switching to Cladribine Tablets from Other High-Efficacy Disease-Modifying Therapies for Relapsing–Remitting Multiple Sclerosis: Opportunities and Challenges." Neurology & Therapy, vol. 15, no. 3, 2026, p. 887, https://doi.org/10.1007/s40120-026-00901-7.